Here's Why AbbVie (ABBV) is a Strong Momentum Stock

AbbVie (ABBV) is highlighted as a strong momentum stock by Zacks, despite its #3 (Hold) Zacks Rank, attributed to its 'A' VGM Score and 'B' Momentum Style Score. The pharmaceutical giant's strategic 2020 acquisition of Allergan has diversified its portfolio beyond Humira, with new immunology drugs Skyrizi and Rinvoq positioned as key growth drivers. Recent positive indicators include a 1.3% share price increase over four weeks and six upward revisions to fiscal 2025 earnings estimates, raising the consensus to $12.28 per share, suggesting continued favorable momentum for the stock.

Analysis

AbbVie (ABBV) presents a compelling case for momentum-oriented investors, underscored by a Zacks 'A' grade for its overall VGM Score and a 'B' for Momentum, despite a neutral #3 (Hold) rank. This positive momentum is substantiated by tangible metrics, including a 1.3% share price appreciation over the past four weeks and a consistent history of positive earnings surprises averaging 2.6%. Fundamentally, the optimistic sentiment is fueled by upward revisions to its earnings outlook; six analysts have raised their fiscal 2025 estimates in the last 60 days, lifting the consensus earnings per share by $0.07 to $12.28. Strategically, the company is navigating the critical post-Humira era, following the loss of patent protection for its flagship drug. The transformative $63 billion acquisition of Allergan in 2020 has been pivotal in diversifying its portfolio, with new immunology drugs Skyrizi and Rinvoq now positioned as the primary long-term growth drivers.

Key Decisions for Investors

• Momentum-focused investors should note the stock's positive short-term signals, including its 'B' Momentum Score and recent upward earnings estimate revisions for fiscal 2025.
• Investors should evaluate AbbVie's strategic transition, closely monitoring the sales growth of Skyrizi and Rinvoq as primary indicators of the company's ability to successfully offset the revenue decline from Humira.
• Despite the positive momentum, the formal Zacks #3 'Hold' rank suggests a balanced risk-reward profile, making it prudent to consider the stock's potential within a diversified healthcare portfolio rather than as a singular high-conviction position.